Santhera Pharmaceuticals Holding AG (XSWX:SANN) Other Net Income (Loss) : CHF0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Santhera Pharmaceuticals Holding AG Other Net Income (Loss)?

Santhera Pharmaceuticals Holding AG's Other Net Income (Loss) for the six months ended in Dec. 2024 was CHF0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 was CHF0.00 Mil.

Santhera Pharmaceuticals Holding AG's quarterly Other Net Income (Loss) stayed the same from Dec. 2023 (CHF0.00 Mil) to Jun. 2024 (CHF0.00 Mil) but then increased from Jun. 2024 (CHF0.00 Mil) to Dec. 2024 (CHF0.00 Mil).

Santhera Pharmaceuticals Holding AG's annual Other Net Income (Loss) declined from Dec. 2022 (CHF0.00 Mil) to Dec. 2023 (CHF-0.00 Mil) but then increased from Dec. 2023 (CHF-0.00 Mil) to Dec. 2024 (CHF0.00 Mil).

Santhera Pharmaceuticals Holding AG Other Net Income (Loss) Historical Data

The historical data trend for Santhera Pharmaceuticals Holding AG's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santhera Pharmaceuticals Holding AG Other Net Income (Loss) Chart

Santhera Pharmaceuticals Holding AG Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Net Income (Loss)

Get a 7-Day Free Trial

Santhera Pharmaceuticals Holding AG Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Santhera Pharmaceuticals Holding AG Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0.00 Mil.

Santhera Pharmaceuticals Holding AG Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Santhera Pharmaceuticals Holding AG's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Santhera Pharmaceuticals Holding AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santhera Pharmaceuticals Holding AG (XSWX:SANN) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

SPHDF:USA SANNz:UK 0QN1:UK

Address

Hohenrainstrasse 24, Pratteln, CHE, 4133

Website

https://www.santhera.com

Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives the majority of its revenue from the European Union.

Santhera Pharmaceuticals Holding AG Headlines

No Headlines